These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 22160062)

  • 1. Diagnosis and management of immune thrombocytopenia in the era of thrombopoietin mimetics.
    Liebman HA; Pullarkat V
    Hematology Am Soc Hematol Educ Program; 2011; 2011():384-90. PubMed ID: 22160062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults.
    Lam MS
    J Oncol Pharm Pract; 2010 Jun; 16(2):89-103. PubMed ID: 19525300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
    Kuter DJ
    Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What's new in the management of chronic primary immune thrombocytopenia in adults and the use of thrombopoietin receptor agonists.
    Newland A
    Med Princ Pract; 2011; 20(4):301-2. PubMed ID: 21576988
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenic purpura: meta-analysis.
    Tumaini Massaro J; Chen Y; Ke Z
    Platelets; 2019; 30(7):828-835. PubMed ID: 30810479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists.
    Rodeghiero F; Carli G
    Ann Hematol; 2017 Sep; 96(9):1421-1434. PubMed ID: 28275823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A United Kingdom Immune Thrombocytopenia (ITP) Forum review of practice: thrombopoietin receptor agonists.
    Thachil J; Bagot C; Bradbury C; Cooper N; Lester W; Grainger JD; Lowe G; Evans G; Talks K; Sibson K; Garg M; Murphy MF; Watson HG; Bolton-Maggs PHB; Watson S; Scully M; Provan D; Newland A; Hill QA
    Br J Haematol; 2018 Feb; 180(4):591-594. PubMed ID: 27879997
    [No Abstract]   [Full Text] [Related]  

  • 8. [Romiplostim: an advance in the treatment of idiopathic thrombocytopenic purpura].
    Mingot Castellano ME
    Methods Find Exp Clin Pharmacol; 2010 Dec; 32 Suppl A():39-43. PubMed ID: 21381287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopenia.
    Michel M; Wasser J; Godeau B; Aledort L; Cooper N; Tomiyama Y; Khellaf M; Wang X
    Ann Hematol; 2015 Dec; 94(12):1973-80. PubMed ID: 26341755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Management of Primary Immune Thrombocytopenia.
    Provan D; Newland AC
    Adv Ther; 2015 Oct; 32(10):875-87. PubMed ID: 26499177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombopoietin receptor agonists: a new immune modulatory strategy in immune thrombocytopenia?
    Schifferli A; Kühne T
    Semin Hematol; 2016 Apr; 53 Suppl 1():S31-4. PubMed ID: 27312161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pathophysiology of ITP revisited: ineffective thrombopoiesis and the emerging role of thrombopoietin receptor agonists in the management of chronic immune thrombocytopenic purpura.
    Gernsheimer TB
    Hematology Am Soc Hematol Educ Program; 2008; ():219-26. PubMed ID: 19074086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus.
    Maroun MC; Ososki R; Andersen JC; Dhar JP
    Lupus; 2015 Jun; 24(7):746-50. PubMed ID: 25416695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adult immune thrombocytopenia and thrombopoietin receptor agonist: Ten years later].
    Ebbo M; Rivière E; Godeau B
    Rev Med Interne; 2021 Jan; 42(1):38-45. PubMed ID: 32712041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current treatment of primary immune thrombocytopenia].
    Lozano ML; Vicente V
    Med Clin (Barc); 2014 May; 142(9):399-405. PubMed ID: 23809409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiology and management of primary immune thrombocytopenia.
    Kashiwagi H; Tomiyama Y
    Int J Hematol; 2013 Jul; 98(1):24-33. PubMed ID: 23702914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Childhood immune thrombocytopenia: role of rituximab, recombinant thrombopoietin, and other new therapeutics.
    Journeycake JM
    Hematology Am Soc Hematol Educ Program; 2012; 2012():444-9. PubMed ID: 23233617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thrombopoietin receptor agonists administration for acute exacerbation of chronic idiopathic thrombocytopenic purpura and subsequent anticoagulant therapy for accompanying deep venous thrombosis of the lower limbs].
    Kawano H; Suzuki T; Ishii S; Wakahashi K; Kawano Y; Sada A; Minagawa K; Takaya T; Yamashita T; Hirata K; Koriyama K; Nagamatsu Y; Matsui T; Katayama Y
    Rinsho Ketsueki; 2014 Jun; 55(6):697-702. PubMed ID: 24975340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management.
    Beltrami-Moreira M; Sharma A; Bussel JB
    Expert Rev Hematol; 2024 Sep; 17(9):595-607. PubMed ID: 39105265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombopoietin Receptor Agonists for the treatment of ITP.
    Cheng G
    Rinsho Ketsueki; 2013 Oct; 54(10):1915-8. PubMed ID: 24064843
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.